

1) Zeissig S, Hammer L, Rath S et al. Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib - First results from the IBD-DACH study EUROPE. Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Page i1657, <https://doi.org/10.1093/ecco-jcc/jjad212.1035>

2) a) Dignass A, Hammer L et al. Proportion of IBD patients with suboptimal control in daily clinical practice – real-world evidence from the IBD Podcast study.

Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i794–i795, <https://doi.org/10.1093/ecco-jcc/jjad212.0507>

b) Blumenstein I, Hammer L, Rath S et al. Steroidgebrauch bei einem hohen Anteil von CED-Patienten – erste Ergebnisse aus der deutschen Kohorte der IBD-DICE-Studie. Z Gastroenterol 2022; 60(08): e638-e639 <https://doi.org/10.1055/s-0042-1755089>

c) Kucharzik T, Rath S, Hammer L et al. IBD patients with early clinical and sonographic improvements achieve better long-term outcomes than patients with clinical improvements alone – one-year interim results of the TRUST BEYOND study

Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i247–i248, <https://doi.org/10.1093/ecco-jcc/jjab232.309>

3) Dignass A, Rath S, Kleindienst T, Stallmach A. Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges. Aliment Pharmacol Ther. 2023 Sep;58(5):492-502. <https://doi.org/10.1111/apt.17622>